KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Operating Leases (2021 - 2025)

Historic Operating Leases for Ionis Pharmaceuticals (IONS) over the last 5 years, with Q3 2025 value amounting to $262.7 million.

  • Ionis Pharmaceuticals' Operating Leases rose 5600.69% to $262.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $262.7 million, marking a year-over-year increase of 5600.69%. This contributed to the annual value of $161.8 million for FY2024, which is 530.8% down from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Operating Leases is $262.7 million, which was up 5600.69% from $164.4 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Operating Leases' 5-year high stood at $262.7 million during Q3 2025, with a 5-year trough of $19.4 million in Q4 2021.
  • For the 5-year period, Ionis Pharmaceuticals' Operating Leases averaged around $165.1 million, with its median value being $168.7 million (2024).
  • Per our database at Business Quant, Ionis Pharmaceuticals' Operating Leases surged by 82085.73% in 2022 and then plummeted by 550.29% in 2025.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Operating Leases stood at $19.4 million in 2021, then soared by 820.86% to $178.9 million in 2022, then decreased by 4.51% to $170.9 million in 2023, then dropped by 5.31% to $161.8 million in 2024, then soared by 62.34% to $262.7 million in 2025.
  • Its last three reported values are $262.7 million in Q3 2025, $164.4 million for Q2 2025, and $159.4 million during Q1 2025.